Morphometric and ultrastructural analysis of human granulosa cells after gonadotrophin-releasing hormone agonist or antagonist

被引:18
|
作者
Centurione, L. [1 ]
Giampietro, F. [2 ]
Sancilio, S. [1 ]
Piccirilli, M. [3 ]
Artese, L. [3 ]
Tiboni, G. M. [2 ]
Di Pietro, R. [1 ]
机构
[1] Univ G dAnnunzio, Dept Biomorphol, I-66013 Chieti, CH, Italy
[2] Univ G DAnnunzio, Dept Med & Ageing Sci, Sect Obstet & Gynaecol, Chieti, Italy
[3] Univ G DAnnunzio, Dept Dent & Stomatol, Chieti, Italy
关键词
electron microscopy; GnRH agonist; GnRH antagonist; granulosa cells; morphometric analysis; IN-VITRO FERTILIZATION; EMBRYO TRANSFER CYCLES; LUTEIN CELLS; OVARIAN STIMULATION; GNRH AGONIST; FOLLICLES; STEROIDOGENESIS; SUBPOPULATIONS; LOCALIZATION; EXPRESSION;
D O I
10.1016/j.rbmo.2010.02.009
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Morphological features of granulosa cells can reflect their functional status. The present study was aimed at comparing possible differences in the fine structure of human granulosa cells exposed to gonadotrophin-releasing hormone (GnRH) agonist or antagonist treatment during ovarian stimulation. Cells were obtained from follicular aspirates of 21 women treated with recombinant follicle-stimulating hormone (rFSH) plus either a GnRH agonist or a GnRH antagonist. Conventional light microscopy procedures and computerized image analysis systems were used to identify different cell type morphological patterns and to quantify different cells distribution. Two morphologically distinct granulosa cell populations, defined as large/pale and small/dark cells, were identified and a different distribution in the two groups of women under investigation was found: a significantly higher percentage in large/pale cells was detected in the agonist-treated women (P < 0.05), whereas the percentage of small/dark cells was significantly higher in the antagonist-treated group (P < 0.05). Ultrastructural observations showed the presence in both cell populations of typical hallmarks of steroidogenic cells, highlighting signs of functional activity in the large/pale cell population. Further investigations are needed to define the possible clinical significance of these morphological findings. (C) 2010, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:625 / 633
页数:9
相关论文
共 50 条
  • [1] Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?
    Lin, Y
    Kahn, JA
    Hillensjö, T
    HUMAN REPRODUCTION, 1999, 14 (04) : 885 - 888
  • [2] Effects of a gonadotrophin-releasing hormone agonist and follicle stimulating hormone on the incidence of apoptosis in human granulosa cells
    Sifer, C.
    Blanc-Layrac, G.
    Bringuier, A. F.
    Madelenat, P.
    Feldmann, G.
    Benifla, J. L.
    HUMAN REPRODUCTION, 2001, 16 : 65 - 65
  • [3] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells
    Tsai, NM
    Hsieh, RH
    Au, HK
    Shieh, MJ
    Huang, SY
    Tzeng, CR
    ROLE OF THE MITOCHONDRIA IN HUMAN AGING AND DISEASE: FROM GENES TO CELL SIGNALING, 2005, 1042 : 531 - 537
  • [4] GONADOTROPHIN-RELEASING HORMONE AGONIST AND ANTAGONIST: FACTORS DRIVING THE PREGANCY OUTCOMES AN EXPLORATORY ANALYSIS
    Al-Inany, H. G.
    Abou-Setta, A. M.
    FERTILITY AND STERILITY, 2011, 96 (03) : S256 - S257
  • [5] Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders
    Xia, Min
    Zheng, Jie
    BMC PREGNANCY AND CHILDBIRTH, 2021, 21 (01)
  • [6] Comparison of clinical outcomes between the depot gonadotrophin-releasing hormone agonist protocol and gonadotrophin-releasing hormone antagonist protocol in normal ovarian responders
    Min Xia
    Jie Zheng
    BMC Pregnancy and Childbirth, 21
  • [7] PLASMA GONADOTROPIN AND GONADOTROPHIN-RELEASING HORMONE LEVELS AFTER INTRANASAL ADMINISTRATION OF GONADOTROPHIN-RELEASING HORMONE
    KATZ, M
    PIMSTONE, BL
    CARR, PJ
    HENDRICKS, S
    SOUTH AFRICAN MEDICAL JOURNAL, 1976, 50 (26): : 998 - 999
  • [8] Human ovarian steroid secretion in vivo: effects of gonadotrophin-releasing hormone agonist versus antagonist (cetrorelix)
    Garcia-Velasco, J. A.
    Isaza, V.
    Vidal, C.
    Landazabal, A.
    Remohi, J.
    Simon, C.
    Pellicer, A.
    HUMAN REPRODUCTION, 2001, 16 : 15 - 16
  • [9] Pregnancy during gonadotrophin-releasing hormone agonist therapy
    Uncu, G
    Benderli, S
    Esmer, A
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 1996, 36 (04): : 484 - 485
  • [10] Adjuvant gonadotrophin-releasing hormone agonist trigger with human chorionic gonadotrophin to enhance ooplasmic maturity
    Pereira, Nigel
    Elias, Rony T.
    Neri, Queenie V.
    Gerber, Rachel S.
    Lekovich, Jovana P.
    Palermo, Gianpiero D.
    Rosenwaks, Zev
    REPRODUCTIVE BIOMEDICINE ONLINE, 2016, 33 (05) : 568 - 574